Rebif

The drug: Rebif
Generic: Interferon beta-1a
The company: Merck KGaA
Patent expiration date: Dec. 31, 2013
Estimated Global Sales 2012: $2.3 billion

The scoop: Rebif is one of those top-selling drugs that rivals shoot at when they're trying to advance a new standard of care for patients. Sanofi ($SNY) went gunning for Rebif in a head-to-head trial with its experimental new drug Lemtrada, coming up with a better score on delaying disease progression. That's a key measure for physicians and patients, though side effects could limit Lemtrada's entry. Novartis' ($NVS) Gilenya, meanwhile, has already been stealing market share. But where Biogen Idec ($BIIB) and Sanofi have been making major progress with new treatments, Merck KGaA has run into a buzzsaw of trouble on the MS front. Its program for the MS drug cladribine--once considered a leading late-stage program--became an epic failure that triggered a company-wide restructuring. Analysts concluded that its Serono acquisition was a bust. But Merck KGaA is still working in the field. An extended-release Rebif program is in Phase I, notes Evaluate Pharma, which could eventually help protect sales.

For more:
Sanofi's Lemtrada beats Rebif in head-to-head MS showdown
Cost and job cuts coming soon to Merck KGaA

Rebif
Read more on

Suggested Articles

Life sciences companies have pivoted quickly during COVID-19 - Syneos Health® is supporting more than 80 active COVID-19 projects, including vaccines.

New York's Covaxx has signed on with three South American nations to provide 140 million doses of its early-stage COVID-19 vaccine.

To get the COVID-19 vaccine out quickly, Pfizer has been running rehearsals at distribution sites, creating "growing confidence," U.S. officials said.